Pharma Industrial India Magazine - May-June 2024

sive life cycle services across the entire value chain. Our goal is to co-create and co-succeed in close partnership with our clients so that they can bring their life-saving medicines to the market as quickly, efficiently, and safely as possible. Q What prompted Syntegon to expand its pharmaceutical processing and packaging business and was there any specific reason to acquire Azbil Telstar? Dr. Andreas Mattern: Telstar is a significant addition to Syn - tegon’s portfolio for liquid pharmaceutical processing. Telstar has a strong experienced team serving pharma, life sciences, and medtech customers around the world, especially in South- ern and Western Europe, the U.S., and India. Freeze-dryers as well as loading and unloading systems including comprehen- sive services are the most important portfolio enhancements for Syntegon and ideally complement its leading vial filling and isolator solutions. With the expanded portfolio, Syntegon will be in an even bet- ter position to offer both pharmaceutical manufacturers and CMOs seamless line solutions from a single source. Moreover, the Syntegon service network will be expanded significantly by the Telstar service engineers, adding geographical coverage, proximity, and application expertise. Telstar’s business will of course also benefit from its integration into the Syntegon Group with its complete solutions for pharmaceutical processing and packaging technology. Q What advantages will pharmaceutical manufacturers and CMOs gain from Syntegon’s expanded portfolio? Dr. Andreas Mattern: Syntegon’s customers will benefit from even more comprehensive solutions, seamless processes, and life cycle services. At the same time, we will jointly capture growth opportunities and expand our market presence. How- ever, Syntegon is not only expanding its offering for pharma- ceutical manufacturers and CMOs through this acquisition. We are also doing this through new technological developments, as we demonstrated at Achema in Frankfurt, Germany, this June. For example, with the new modular bioprocessing platform (MBP), we now also offer biopharmaceutical manufacturers seamless and complete solutions along the entire production chain. The innovative design of the MBP allows customers to profit from shorter lead times and lower costs, without compro - mising on quality. The MBP is a highly flexible, fully integrated and automated solution for biologic drug substances, which answers the most pressing challenges in biopharmaceutical production. PHARMA INDUSTRIALINDIA · MAY-JUN 24 19 INTERVIEW